13Feb 2021
Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival With Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses From the Phase 3 JAVELIN Lung 200 Trial

Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival With Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses From the Phase 3 JAVELIN Lung 200 Trial

Avelumab is a human anti–programmed cell death 1 ligand 1 (PD-L1) IgG1 antibody that has shown durable antitumor activity and an acceptable safety profile in patients with a range of tumor types [1–7].

  • #pulmonology

Like

Save

Share